OTC Markets Group Inc. (OTCQX: OTCM) and PR Newswire welcomed investor relations professionals from some of Europe’s largest corporations to the Westminster Hotel in central Paris on 21st January to take part in a breakfast forum aimed at educating European global companies about the OTCQX® and OTCQB® marketplaces in the US and providing guidance and best practices on cost-effectively reaching US investors.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7425751-otc-markets-us-investor-strategies/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Just 70 years ago the fate of the world hung by a thread. America was fighting a two-front war against Nazi Germany and Imperial Japan. Titanic battles, on a scale never seen before or since, blazed across two vast oceans and three huge continents. Our fear was great. Our anxiety real. Our victory was far from certain. If we won, we would preserve our freedom.
Now the story of that struggle unfolds inside the new Campaigns of Courage: European and Pacific Theaters pavilion opening December 13, 2014 at The National WWII Museum in New Orleans. Assembled for the first time in one space is the epic story of America’s citizen soldiers on the battlefields. Visitors will discover how the war that changed the world was fought and won through the words and deeds of the participants themselves – those called the Greatest Generation.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7399151-national-wwii-museum-newest-exhibit-campaigns-of-courage-european-and-pacific-theaters/
The European Space Agency (ESA) has joined the CEMS global alliance as the first partnership of its kind, at a meeting in Brussels last month.
Established in 1988 by four leading European business schools (Università Bocconi, ESADE, HEC Paris and the University of Cologne), CEMS has grown into a 29-school partnership, collaborating with 70 Corporate, four Social Partners, together offering a Masters in International Management (MIM) programme.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7396551-European-Space-Agency-joins-CEMS/
Erreà 3DWear is proud to join forces with Stade Toulousain and its players in the most important time of the season.
Erreà 3DWear technical base layer line features the most sophisticated and innovative fabrics. Stade Toulousain's players wear it to improve their performance during matches, when each single molecule of energy is needed to confront the hardest adversaries and fight fatigue.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7391651-errea-3D-wear-stade-toulousain/
In its annual report on the EU budget published today, the European Court of Auditors (ECA) warns that the budget system is too focused on just getting funds spent and needs to place more emphasis on achieving results. As independent auditor, the ECA signed off the 2013 accounts of the European Union, but stresses that the management of EU spending is not yet good enough overall - either at EU level or in the Member States.
Throughout the 2007 to 2013 spending period, say the EU Auditors, the priority was given to spending the money - ‘use it or lose it’ - rather than to achieving good results. For instance, the choice of projects to receive EU funds focused first on disbursing the EU money available, secondly on complying with the rules, and only then - and to a limited extent - on results and impact.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762585-EU-must-focus-on-better-results/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
